Human cell-grown HIV-1 vaccine protects macaques against challenge with SIVmac.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Human cell-grown HIV-1 vaccine protects macaques against challenge with SIVmac.

Symp Nonhum Primate Models AIDS. 1992 Nov 17-20;10:abstract no. 113. Unique Identifier : AIDSLINE PRIM10/93200952
Cranage MP; Polyanskaya N; McBride B; Cook N; Greenaway P; Dennis M; Ashworth T; Farrar G; Division of Pathology, PHLS Centre for Applied Microbiology &; Research, Porton Down, Salisbury, U.K.

Abstract: The recent observations that protection against SIVmac challenge correlates with anti-cell antibody responses, that cells alone can elicit a degree of anti-viral protection and that protection is limited to challenge stocks grown in human cells, has lead to a re-evaluation of the role of anti-cell antibodies in SIV vaccine protection. To investigate the specificity of protection elicited by formaldehyde-inactivated, partially-purified vaccines, 4 rhesus macaques were immunized at 0, 4, 8 and 16 weeks with C8166 cell-grown HIV-1 (GB8), administered in saf-1. All animals were protected from challenge with the 32H reisolate of SIVmac251 grown on the same cell line. Challenge experiments with SIVsmB670, grown on human PBMC, are in progress. HIV-1 and SIV vaccine preparations contained cell substrate proteins including MHC class 1 and class 2 antigens and CD4. Both vaccines elicited humoral responses against lysates of uninfected C8166 cells which were quantitatively similar in ELISA. The principle anti-cell response in both HIV-1 and SIV vaccinated macaques detected by Western blotting and immunoprecipitation was to MHC class 1 antigens; no anti MHC class 2 or anti CD4 activity was seen. Reactivity to an unidentified protein of 70KD was also detected. It will be important to determine if alloreactive responses can also mediate protection against immunodeficiency viruses.

Keywords: Animal Antibody Formation AIDS Vaccines/*IMMUNOLOGY Cell Line Histocompatibility Antigens Class I/IMMUNOLOGY Human HIV-1/*IMMUNOLOGY HLA-D Antigens/IMMUNOLOGY Lymphocytes/IMMUNOLOGY Macaca mulatta Simian Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*PREVENTION & CONTROL *SIV ABSTRACT
930630
M9361068

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .